HCrrOOQL ABSTRACT 
fGive nu mber and ahhrw jafprt titled C 1 ^ line* not to axaaad 75 characters per line) 
Introduction of Chemotherapy Resistance into Normal Marrow cells 
STOCK CSAIFMAN: 
{ Albert Deisseroth, M.D., Ph. D. , John Kavanagh, m.u 
and Richard Champlin / M.D. 
Patient Eligibility; Ct**ity lines not to aocaad 75 character* per line) 
1. Patients with poor prognosis ovarian cancer who have failed 
initial therapy or reinduction therapy including platinum 
analogues, and who have not been previously exposed to Taxol. 
2. Age 18 to 60 years 
3. Performance status 0-2 and acceptable cardiac, renal, hepatic, 
and pulmonary functions. 
teaftlEnt Plan: (Inclixie dra> adjustments CTN-nty Uxm net to moM 75 ctoctea per 11m) 
1. Patients with disease which is refractory to conventional dose 
combination chemotherapy will have marrow harvested following 
administration of conventional dose chemotherapy. The autologous 
marrow will be subjected to concentration in the COBE 2991 con- 
centrator, CD34 selection in the CellPro Stem Cell Concentrator, and 
the cells modified with a safety-modified retrovirus which carries a 
CDNA for the multidrug resistance mRNA (MDR-1) . 
2. Autologous bone marrow infusion will take place following delivery of 
high dose cytoxan (1.7 g/m 2 /d) and thiotepa (225 mg/m 2 /d) each day for 
three days. Benadryl 25 mg and solucortef 100 mg will be given before 
bone marrow infusion to prevent anaphylaxis. 
3. Patients will receive prophylactic oral antibiotics and blood products 
irradiated with 2500 rads. 
4. Conventional dose Taxol starting at 135 mg/m 2 Cl qdxl each course, 
which will be given at increasing doses each course to tolerance given 
following recovery from transplant every three weeks. The patients 
will be treated for three courses at 135 mg/m 2 , then 200 mg/m 2 and then 
250 mg/m 2 . The doses will continue to increase unless there is 
toxicity at unacceptable levels. 
Recombinant DNA Research, Volume 17 [661] 
